CN116251063A - Amoxicillin and clavulanate potassium dry suspension and preparation method thereof - Google Patents
Amoxicillin and clavulanate potassium dry suspension and preparation method thereof Download PDFInfo
- Publication number
- CN116251063A CN116251063A CN202111490314.0A CN202111490314A CN116251063A CN 116251063 A CN116251063 A CN 116251063A CN 202111490314 A CN202111490314 A CN 202111490314A CN 116251063 A CN116251063 A CN 116251063A
- Authority
- CN
- China
- Prior art keywords
- amoxicillin
- percent
- clavulanate
- dry suspension
- potassium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the field of pharmaceutical preparations, in particular to an amoxicillin and clavulanate potassium dry suspension and a preparation method thereof. The optimal dry suspension prescription composition is determined by continuously optimizing the process screening of the prescription of the amoxicillin and clavulanate potassium dry suspension and improving the preparation method thereof, screening the types of the suspension and carrying out preliminary evaluation on the sedimentation ratio.
Description
Technical Field
The present invention relates to the field of pharmaceutical formulations. More specifically, the invention relates to an amoxicillin and clavulanate potassium dry suspension and a preparation method thereof.
Background
Chemical name of amoxicillin (CAS: no. 26787-78-0): (2S, 5R, 6R) -3, 3-dimethyl-6- [ (R) - (-) -2-amino-2- (4-hydroxyphenyl) acetamido ] -7-oxo-4-thia-1-azabicyclo [3.2.0] heptane-2-carboxylic acid trihydrate. The molecular weight 419.46, the chemical structural formula is shown as formula 1, is a broad-spectrum penicillin antibiotic, belongs to beta-lactam inhibitors, and can effectively target various gram-positive bacteria and partial gram-negative bacteria. Beta-lactams work in concert with penicillin binding proteins to activate autolyases in the bacterial cell wall by inhibiting synthesis of the bacterial cell wall peptidoglycan layer, causing cell wall lysis and thereby destroying bacterial cells.
Chemical name of potassium clavulanate (CAS: no. 61177-45-5): the (Z) - (2S, 5R) -3- (2-hydroxyethylidene) -7-oxo-4-oxa-1-azabicyclo-3.2.0-heptane-2-carboxylic acid potassium has a molecular weight of 237.251, a chemical structural formula shown as formula 2, and can be used alone with amoxicillin to play a better bactericidal effect as a beta-lactamase inhibitor with only weak bactericidal activity. Beta-lactamase inhibitors increase the antibacterial efficacy of amoxicillin by irreversibly binding to the catalytic site of beta-lactamase, resulting in resistance of lactamase to the original beta-lactam ring of amoxicillin. Potassium amoxicillin clavulanate is FDA approved for use in aspiration pneumonia, acute bacterial sinusitis, urinary tract infection, acute otitis media, skin and soft tissue infection.
Currently, the dosage forms widely used clinically include tablets, capsules and dry suspensions. The tablet and the capsule have poor oral compliance for children and old people, and the dry suspension has the advantages of convenient administration, medicine taking in different doses and good oral compliance, but has poor stability, and adverse reaction is easy to occur for patients.
Disclosure of Invention
Based on the problems existing in the prior art, the invention continuously screens and optimizes the process of the amoxicillin and clavulanate potassium dry suspension prescription and improves the preparation method thereof, the optimal dry suspension prescription composition is determined by screening the species of the suspension and carrying out preliminary evaluation on the sedimentation ratio, and meanwhile, the invention provides the preparation method of the amoxicillin and clavulanate potassium dry suspension, which has the advantages of simple and feasible preparation method, satisfactory dissolution curve and good stability, and can carry out single-dose packaging.
The prescription process screening process of the amoxicillin and clavulanate potassium dry suspension comprises the following steps:
the suspending agent has the effect of increasing the viscosity of the dispersion medium and slowing down the sedimentation velocity of the particles, and the good suspending agent should have good suspending effect, be non-sticky and easy to redisperse. The invention screens the suspending agent types mainly used, including hypromellose E50, hypromellose E3 and hypromellose E6, and carries out preliminary evaluation through sedimentation ratio. The sedimentation ratio operation is carried out according to the sedimentation volume ratio of oral suspension in Chinese pharmacopoeia 2020 edition, and the sedimentation volume ratio is regulated to be not lower than 0.90. And adding Shui Zhen into the dry suspension according to a certain proportion, shaking and uniformly dispersing. 50ml of the sample was taken with a stopper cylinder, sealed, and shaken vigorously for 1 minute, and the starting height H of the suspension was recorded 0 Standing for 3 hours, and recording the final height H of the suspension, wherein the final height H is calculated according to the following formula: sedimentation volume ratio = H/H 0 The prescription composition is shown in Table 1.
TABLE 1
The preliminary measurement of the sedimentation ratio shows that after standing for 3 hours, the sedimentation volume ratio of the prescription 1 is 1.00, no obvious sedimentation is found, the suspension effect is good, the sedimentation volume ratios of the prescriptions 2 and 3 are 0.84 and 0.88, obvious sedimentation occurs, but in the process of dissolving the prescription 1 powder, the phenomenon of wall sticking and caking occurs, and the problem that the fluidity of the prescription 1 is poor due to the fact that the viscosity of the hypromellose E50 is too large is considered. Therefore, the inventor adjusts the proportion of the hypromellose E50, the xanthan gum and the silicon dioxide, when the proportion of the hypromellose E50, the xanthan gum and the silicon dioxide is 3:1:5, the obtained dry suspension powder has good fluidity, and no caking and wall sticking phenomenon is caused in the water adding dissolution process, and no obvious sedimentation is seen.
The invention aims to provide an amoxicillin and clavulanate potassium dry suspension, which is realized by the following steps: the amoxicillin and clavulanate potassium dry suspension mainly comprises amoxicillin, clavulanate potassium, a suspending agent, maltodextrin, citric acid, a lubricant and a flavoring agent;
the suspending agent is selected from one or more of hypromellose E50, hypromellose E3, hypromellose E6 and xanthan gum, preferably xanthan gum and hypromellose E50;
the lubricant is selected from one or more of magnesium stearate, talcum powder, silicon dioxide and colloidal silicon dioxide, preferably silicon dioxide;
the weight part ratio of the hydroxypropyl methylcellulose E50 to the xanthan gum to the silicon dioxide is 3:1:5;
the flavoring agent is one or more selected from saccharin sodium, apple essence, aspartame, coconut essence, and orange essence, preferably aspartame, orange essence, and apple essence.
Further preferably, the amoxicillin and clavulanate potassium dry suspension comprises the following raw and auxiliary materials in parts by weight: 37.4 to 44.1 percent of amoxicillin,
9.1 to 12.9 percent of clavulanate potassium,
1.7 to 4.1 percent of xanthan gum,
6.0 to 10.7 percent of hydroxypropyl methylcellulose E,
maltodextrin 0.7-2.9 wt%,
citric acid 0.012-0.048%,
11.9 to 29.8 percent of silicon dioxide,
15.5 to 21.5 percent of aspartame,
0.048 to 0.167 percent of orange essence,
apple essence 0.048% -0.167%;
further preferably, the amoxicillin and clavulanate potassium dry suspension comprises the following raw and auxiliary materials in parts by weight:
41.2 percent of amoxicillin,
10.3 percent of clavulanate potassium,
hydroxypropyl methylcellulose E50.6%,
3.2 percent of xanthan gum,
2.3 percent of maltodextrin,
citric acid 0.026 percent,
16% of silicon dioxide,
aspartame 17.1,
0.137 percent of orange essence,
apple essence 0.137%;
the invention also aims to provide a preparation method of the amoxicillin and clavulanate potassium dry suspension, which comprises the following concrete implementation steps:
(1) Weighing the xanthan gum and the aspartame with the prescription amount, drying at 65 ℃ and normal pressure for 5 hours, and sieving maltodextrin, orange essence and apple essence by a 80-mesh sieve;
(2) Weighing hydroxypropyl methylcellulose E50, xanthan gum, aspartame, citric acid, amoxicillin, potassium clavulanate and silicon dioxide according to the prescription amount, and uniformly mixing;
(3) Adding the orange essence and the apple essence with the prescription amounts into the mixed powder obtained in the step (2), and uniformly mixing;
(4) And (5) carrying out single-dose split charging on the mixed powder.
Compared with the prior art, the amoxicillin and clavulanate potassium dry suspension prepared by the invention has good stability, convenient administration and good oral compliance for the aged and children.
Drawings
Fig. 1 is an in vitro dissolution profile of the amoxicillin potassium clavulanate dry suspension of examples 1-2.
Fig. 2 shows in vitro dissolution curves of amoxicillin and clavulanate potassium dry suspensions of examples 3 to 4.
Fig. 3 is an in vitro dissolution profile of the amoxicillin potassium clavulanate dry suspension of comparative examples 1-2.
Detailed Description
The invention will be further illustrated by the following examples, which are given by way of illustration only and are not intended to be limiting, so that simple modifications of the invention, given its method, are within the scope of the invention.
On the basis that the sedimentation volume ratio is not lower than 0.90, examples 1 to 4 are set, and under the condition of changing the prescription and the amount of the dry suspension, comparative examples 1 to 2 are set so as to perform investigation on stability and related material content indexes, and the specific prescription ratio condition is shown in Table 2.
TABLE 2
Preparation process
Examples 1 to 4
(1) Weighing the xanthan gum and the aspartame with the prescription amount, drying at 65 ℃ and normal pressure for 5 hours, and sieving maltodextrin, orange essence and apple essence by a 80-mesh sieve;
(2) Weighing hydroxypropyl methylcellulose E50, maltodextrin, xanthan gum, aspartame, citric acid, amoxicillin, potassium clavulanate and silicon dioxide according to the prescription amount, and uniformly mixing;
(3) Adding the orange essence and the apple essence with the prescription amounts into the mixed powder obtained in the step (2), and uniformly mixing;
(4) And (5) carrying out single-dose split charging on the mixed powder.
Comparative example 1
(1) The orange essence and the apple essence with the prescription amounts are sieved by a 80-mesh sieve;
(2) Weighing hydroxypropyl methylcellulose E50, maltodextrin, xanthan gum, aspartame, citric acid, amoxicillin, potassium clavulanate and silicon dioxide according to the prescription amount, and uniformly mixing;
(3) Adding the orange essence and the apple essence with the prescription amounts into the mixed powder obtained in the step (2), and uniformly mixing;
(4) And (5) carrying out single-dose split charging on the mixed powder.
Comparative example 2
(1) Weighing the prescription amount of xanthan gum and aspartame, drying at 65 ℃ and normal pressure for 5 hours, and sieving the orange essence and the apple essence with a 80-mesh sieve;
(2) Weighing hydroxypropyl methylcellulose E50, mannitol, xanthan gum, aspartame, citric acid, amoxicillin, potassium clavulanate and silicon dioxide with the prescribed amount, and uniformly mixing;
(3) Adding the orange essence and the apple essence with the prescription amounts into the mixed powder obtained in the step (2), and uniformly mixing;
(4) And (5) carrying out single-dose split charging on the mixed powder.
Verification embodiment
And (3) carrying out single-dose split charging on the amoxicillin and clavulanate potassium dry suspension prepared in the examples and the comparative examples, putting the amoxicillin and clavulanate potassium dry suspension into an aluminum-plastic composite bag, and placing the amoxicillin and clavulanate potassium dry suspension for 6 months under the condition of 30 ℃ and 75% RH for acceleration test. The content, total impurities, fluorescence and dissolution curves are detected in the steps of 0, 1, 2, 3 and 6 respectively, 900mL of water is taken, the water temperature is 37 ℃, the rotating speed is 75rpm/min, and the sampling time is 30min. The stability of the formulation was examined, the results of the accelerated test of the samples of each example are shown in Table 3, the results of the total impurity/fluorescence test are shown in Table 4, and the results of the dissolution test are shown in FIG. 3.
TABLE 3 accelerated test results for samples of examples
As can be seen from the results of the contents in Table 3, the amoxicillin contents in examples 1 to 4 were not reduced after 6 months of the accelerated test, and the contents in comparative examples 1 and 2 were slightly reduced; the potassium clavulanate content of examples 1 to 4 was slightly reduced and the degradation of potassium clavulanate was evident for comparative examples 1 and 2. The amoxicillin and clavulanate potassium dry suspension prepared by the invention has better stability.
TABLE 4 results of Total impurity/fluorescence experiments for samples of various examples
As can be seen from Table 4, under the condition of acceleration test, the related substances of amoxicillin and clavulanate in examples 1-4 are not changed obviously, the related substances in comparative examples 1 and 2 are increased obviously, and further, the stability of the prescription of the amoxicillin and clavulanate potassium dry suspension prepared by the invention is proved, and the quality of active drugs can be ensured better.
Claims (10)
1. The amoxicillin and clavulanate potassium dry suspension is characterized by mainly comprising amoxicillin, clavulanate potassium, a suspending agent, xanthan gum, hypromellose E50, citric acid, a lubricant and a flavoring agent.
2. A dry suspension of amoxicillin and clavulanate according to claim 1 wherein the lubricant is selected from one or more of magnesium stearate, talc, silica, colloidal silica.
3. The amoxicillin potassium clavulanate dry suspension of claim 2, wherein the lubricant is silica.
4. A dry suspension of amoxicillin and clavulanate according to claim 3, wherein the ratio of the mass fractions of the hypromellose E50, the xanthan gum and the silicon dioxide is 3:1:5.
5. The amoxicillin potassium clavulanate dry suspension according to claim 4, wherein the flavoring agent is selected from one or more of saccharin sodium, apple essence, aspartame, coconut essence, orange essence.
6. The amoxicillin potassium clavulanate dry suspension according to claim 5, wherein the flavouring agent is aspartame, orange essence and apple essence.
7. The amoxicillin and clavulanate potassium dry suspension according to claim 6, which is characterized by comprising the following raw and auxiliary materials in parts by weight:
37.4 to 44.1 percent of amoxicillin,
9.1 to 12.9 percent of clavulanate potassium,
1.7 to 4.1 percent of xanthan gum,
6.0 to 10.7 percent of hydroxypropyl methylcellulose E,
maltodextrin 0.7-2.9 wt%,
citric acid 0.012-0.048%,
11.9 to 29.8 percent of silicon dioxide,
15.5 to 21.5 percent of aspartame,
0.048 to 0.167 percent of orange essence,
apple essence 0.048-0.167%.
8. The amoxicillin and clavulanate potassium dry suspension according to claim 7, which is characterized by comprising the following raw and auxiliary materials in parts by weight:
41.2 percent of amoxicillin,
10.3 percent of clavulanate potassium,
hydroxypropyl methylcellulose E509.6%,
3.2 percent of xanthan gum,
2.3 percent of maltodextrin,
citric acid 0.026 percent,
16% of silicon dioxide,
17.1 percent of aspartame,
0.137 percent of orange essence,
apple essence 0.137%.
9. The method for preparing the amoxicillin and clavulanate potassium dry suspension according to any one of claims 1 to 8, which is characterized in that the method comprises the following concrete implementation steps:
(1) Weighing xanthan gum and aspartame, oven drying, sieving maltodextrin, orange essence and apple essence;
(2) Weighing hypromellose E50, xanthan gum, aspartame, citric acid, amoxicillin, potassium clavulanate and silicon dioxide, and uniformly mixing;
(3) Adding orange essence and apple essence into the mixed powder obtained in the step (2), and uniformly mixing;
(4) And (5) sub-packaging the mixed powder.
10. The amoxicillin and clavulanate potassium dry suspension preparation method according to claim 9, characterized in that the preparation method comprises the following concrete implementation steps:
(1) Weighing the xanthan gum and the aspartame with the prescription amount, drying at 65 ℃ and normal pressure for 5 hours, and sieving maltodextrin, orange essence and apple essence by a 80-mesh sieve;
(2) Weighing hydroxypropyl methylcellulose E50, xanthan gum, aspartame, citric acid, amoxicillin, potassium clavulanate and silicon dioxide according to the prescription amount, and uniformly mixing;
(3) Adding the orange essence and the apple essence with the prescription amounts into the mixed powder obtained in the step (2), and uniformly mixing;
(4) And (5) carrying out single-dose split charging on the mixed powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111490314.0A CN116251063A (en) | 2021-12-08 | 2021-12-08 | Amoxicillin and clavulanate potassium dry suspension and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111490314.0A CN116251063A (en) | 2021-12-08 | 2021-12-08 | Amoxicillin and clavulanate potassium dry suspension and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116251063A true CN116251063A (en) | 2023-06-13 |
Family
ID=86682972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111490314.0A Pending CN116251063A (en) | 2021-12-08 | 2021-12-08 | Amoxicillin and clavulanate potassium dry suspension and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116251063A (en) |
-
2021
- 2021-12-08 CN CN202111490314.0A patent/CN116251063A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101816635B (en) | Cephalosporin suspension granule and preparation method thereof | |
| JPH11512398A (en) | Pharmaceutical prescription | |
| JP2004522782A (en) | Oral pharmaceutical composition of cefpodoxime proxetil | |
| JP4731777B2 (en) | Oral pharmaceutical composition | |
| CN109432044B (en) | Tebipenem pivoxil fine granule and preparation method thereof | |
| CN1681497A (en) | Dispersible tablets for oral administration | |
| CN102258495B (en) | Cefprozil tablet and preparation method thereof | |
| CN102885811B (en) | Oral preparation containing tebipenem pivoxil | |
| CN102875573B (en) | Cefixime compound and pharmaceutical composition thereof | |
| WO2018142336A1 (en) | Lamotrigine suspension dosage form | |
| CN103110596B (en) | Cefprozil dispersible tablet and preparation method thereof | |
| CN103330685B (en) | Cefaclor granule and preparation method thereof | |
| CN103524533A (en) | Cefprozil compound, and dispersible tablets, dry suspension and preparation method thereof | |
| CN103145733B (en) | Amoxicillin compound and pharmaceutical composition of amoxicillin compound and potassium clavulanate | |
| CN109248150B (en) | Amoxicillin and clavulanate potassium preparation and preparation method thereof | |
| CN103446075A (en) | Cefaclor capsule and preparation method thereof | |
| CN116251063A (en) | Amoxicillin and clavulanate potassium dry suspension and preparation method thereof | |
| CN105534922A (en) | Cefixime granules and preparation method thereof | |
| CN104873501A (en) | Sulbactam sodium composition for treating infectious diseases | |
| CN102327270B (en) | Beta-lactam compound antibiotic composition | |
| CN109908104B (en) | Amoxicillin capsule and preparation method thereof | |
| CN103405387B (en) | A kind of new Cefixime suspension and preparation method thereof | |
| JP5799062B2 (en) | Granular solid formulation containing tosufloxacin | |
| CN104473901A (en) | Cefdinir capsule and preparation method thereof | |
| CN113476415A (en) | Lurasidone hydrochloride tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication |